盐酸坦索罗辛联合抗生素治疗慢性前列腺炎的疗效对比分析

Comparison on the effects of tamsulosin and antibioeic for chronic prostatitis

目的探讨慢性前列腺炎（chronic Prostatitis，CP）的有效治疗方法。方法198例慢性前列腺炎患者随机分成A、B、c三组，A组：坦索罗辛联合抗生素67例：B组：抗生素66例；c组：抗生素联合普适泰65例，3种方法各治疗2个月，随访1～3年，对比治疗前后3种疗法的疗效。结果A组前列腺炎症状指数（CPSI）平均由治疗前的18．6±3．2减少到治疗后的4．4±2．6，CPSI分值减少14．2，B组和c组的CPSI平均由治疗前的15．3±3．2、15．6±3．3减少到治疗后的7．3±0．1和6．2±2．0，B、C组的CPSI的平均分值分别减少8．0、11．4。经过2个月治疗，A组、B组、c组的前列腺液（EPS）镜检WBC〈10／Hp的患者分别为54例（80．1％），42例（63．3％）和48例（73．8％）。A组、B组、c组细菌培养转阴的患者分别为9例（9／1181．9％），6例（6／1154．4％），7例（7／1163．6％）。A组与B、C二组在治疗前后EPS常规恢复正常和细菌转阴率间比较差异有统计学意义；A组与B、c组之间疗效对比，经过方差分析，X2=8．7，P〈0．05，差异有统计学意义，联合抗生素坦索罗辛胶囊治疗CP的疗效明显优于其他二组。结论联合抗生素坦索罗辛胶囊治疗CP疗效满意。

Objectives To evaluate the effects of combined therapies for chronic prostatitis. Methods A total of 198 patients with chronic prostatitis were randomly divided into 3 groups： Group A ：67 patients underwent combination of tamsulosin and antibiotic ; group B ： antibiotic group included 66 patients ; group C ：65 patients under- went combination of antibiotherapy and Pu - shi - tai Capsules. The treatment course for each group was 2 months. The fellow up lasted for 1 - 3 yeats. Comparison and analysis were made on the therapeutic effects of 3 therapies. Results In 3 groups, CPSI scores were reduced equally from 18.6 ± 3.2, 15.3 ± 3.2, and 15.6 ± 3.3 before treatment to 4.4 ± 2.6, 7.3 ± 0.1, and 6.2 ± 2.0 after treatment. Mean CPSI scores had decroased by 14.2, 8.0, and 11.4 respectively. After 2 months treatment, the number of the patients, whose EPS became normal（ WBC 〈 10/ HP） , were 54（80.1% ） ,42（63.3% ） ,and 48（73.8% ） in group A B C respectively. The bacterium negative rate in group A B C were 81.93% （9/11） , 54.4% （6/11） ,and 63.6% （7/11） respectively. There was significant difference between group A and the other two groups. （ x2 = 8.7, p 〈 0.01 ）. The curative effect of combination of tamsulosin and antibiotic was significantly better than that of the other two therapies. Conclusions The curative effect of combination of tamsulosin and antibiotic was satisfactory for chronic prostatitis.